/ /

CLINICAL

End-stage glaucoma requires outside-of-the-box managementAlthough the aim of glaucoma management is to maintain visual function, the role of the ophthalmologist does not end once a patient has lost useful vision. Robert L. Stamper, MD, discussed care for patients with end-stage glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
Welcome to the 2017 Glaucoma 360Adrienne Graves, PhD, and Andrew Iwach, MD, welcome attendees to Glaucoma 360 with their focus set on next year's conference, February 9, 2018 in San Francisco.
What you missed at Glaucoma 360 this year
What you missed at Glaucoma 360 this yearSee the highlights and program overview from the Glaucoma Research Foundation's 2017 Glaucoma 360!
5 reasons to upgrade patients from monovision to multifocalsMany optometrists use the “if it aint broke, don’t fix it” excuse for not fitting multifocals. It is time for ODs to get comfortable with multifocal contact lenses and the opportunity they provide our practices as well as the ability they give us to meet modern patient demands.
5 observations about corticosteroids for DME treatmentFindings from studies investigating intravitreal corticosteroids for treatment of diabetic macular edema (DME) provide information about their efficacy and safety, including some understanding of how they compare with anti-VEGF therapy.
Studying aqueous humour outflow with aqueous angiographyA pioneering dye-based technique that enables aqueous humour outflow to be studied has the potential to improve glaucoma angle-based procedures and surgery outcomes.
Nystagmus diagnosis begins with thorough eye examA careful clinical workup, along with genetic testing, can help pinpoint what is behind congenital and infantile nystagmus.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
Inhibition of PlGF shows additional features compared to VEGF inhibition
Inhibition of PlGF shows additional features compared to VEGF inhibitionAnti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.